FORNEBU, Norway, April 30, 2025 /PRNewswire/ — Aker Horizons (OSE: AKH) will publish its financial results for the first quarter 2025 on Thursday 8 May 2025, at 07:00 CEST. An online presentation of the results will be held on the same day at 08:30 CEST.

Date: Thursday 8 May 2025Time: 08:30 CESTLanguage: EnglishLink: https://akerhorizons.com/investors

Questions can be submitted prior to and during the presentation to ir@akerhorizons.com

For further information, please contact:Jonas Gamre, Investor Relations, Tel: +47 97 11 82 92Email: jonas.gamre@akerhorizons.comMats Ektvedt, Media, Tel: +47 41 42 33 28Email: mats.ektvedt@corpcom.no

About Aker Horizons

Aker Horizons develops green energy and green industry to accelerate the transition to Net Zero. The company is active in renewable energy, carbon capture and sustainable industrial assets. As part of the Aker group, Aker Horizons applies industrial, technological and capital markets expertise with a planet-positive purpose to drive decarbonization globally. Aker Horizons is listed on the Oslo Stock Exchange and headquartered in Fornebu, Norway. Across its portfolio, the company is present on five continents.www.akerhorizons.com

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/aker-horizons/r/aker-horizons-asa–invitation-to-presentation-of-first-quarter-results-2025,c4143825

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

KuCoin Launches KCS Loyalty Level Program: Redefine the KCS Ecosystem and Unlock New Privileges

VICTORIA, Seychelles, March 7, 2025 /PRNewswire/ — KuCoin, a leading global cryptocurrency…

Binance Introduces Agent OS to Connect AI Applications to Financial Infrastructure

New developer platform connects AI applications to Binance trading, market data, wallets,…

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in…